NEW YORK – XPhyto Therapeutics said on Thursday that it has signed a distribution agreement with TechUnit to distribute XPhyto's COVID-ID Lab test in the Czech Republic.
Under the agreement, TechUnit has the right to distribute and sub-distribute the test on a nonexclusive basis, with the potential for territorial exclusivity based on performance. XPhyto said in a statement that the companies are "reviewing opportunities" for distribution of the test in additional territories, including Hungary, Slovakia, Ukraine, and Russia.
Vancouver, British Columbia-based XPhyto also said it will provide TechUnit with technical training and product, strategy, and marketing support.
Financial and other terms of the deal were not disclosed.
The RT-PCR test doesn't require RNA extraction, needing only a 20-minute PCR run. Once the sample is processed, it's placed on a chip, which can detect the virus in five minutes, the company said. The test, which was developed with German diagnostics firm 3a-diagnostics, received CE marking in March. XPhyto acquired 3a-diagnostics for $4.6 million in July of last year.